The FDA on March 3 expanded Eli Lilly’s Verzenio’s use in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer in patients that have a high risk of recurrence. Patients will no longer require a Ki-67 biomarker test to receive the drug, and will instead be identified based on nodal status, tumor size and grade. Verzenio was first approved as an adjuvant breast cancer therapy in 2021. The CDK4/6 inhibitor currently holds covered or better status for 97% of all insured lives under the pharmacy benefit. 15% of lives have preferred access to Verzenio, growing to 39% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 3/8/23